The Inner Ear and Olfaction Lab, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
Institute of Physiology, Department of Biomedical Research (DBMR), University of Bern, 3012 Bern, Switzerland.
Cells. 2022 Aug 5;11(15):2431. doi: 10.3390/cells11152431.
Hearing loss affects over 460 million people worldwide and is a major socioeconomic burden. Both genetic and environmental factors (i.e., noise overexposure, ototoxic drug treatment and ageing), promote the irreversible degeneration of cochlear hair cells and associated auditory neurons, leading to sensorineural hearing loss. In contrast to birds, fish and amphibians, the mammalian inner ear is virtually unable to regenerate due to the limited stemness of auditory progenitors, and no causal treatment is able to prevent or reverse hearing loss. As of today, a main limitation for the development of otoprotective or otoregenerative therapies is the lack of efficient preclinical models compatible with high-throughput screening of drug candidates. Currently, the research field mainly relies on primary organotypic inner ear cultures, resulting in high variability, low throughput, high associated costs and ethical concerns. We previously identified and characterized the phoenix auditory neuroprogenitors (ANPGs) as highly proliferative progenitor cells isolated from the A/J mouse cochlea. In the present study, we aim at identifying the signaling pathways responsible for the intrinsic high stemness of phoenix ANPGs. A transcriptomic comparison of traditionally low-stemness ANPGs, isolated from C57Bl/6 and A/J mice at early passages, and high-stemness phoenix ANPGs was performed, allowing the identification of several differentially expressed pathways. Based on differentially regulated pathways, we developed a reprogramming protocol to induce high stemness in presenescent ANPGs (i.e., from C57Bl6 mouse). The pharmacological combination of the WNT agonist (CHIR99021) and TGFβ/Smad inhibitors (LDN193189 and SB431542) resulted in a dramatic increase in presenescent neurosphere growth, and the possibility to expand ANPGs is virtually limitless. As with the phoenix ANPGs, stemness-induced ANPGs could be frozen and thawed, enabling distribution to other laboratories. Importantly, even after 20 passages, stemness-induced ANPGs retained their ability to differentiate into electrophysiologically mature type I auditory neurons. Both stemness-induced and phoenix ANPGs resolve a main bottleneck in the field, allowing efficient, high-throughput, low-cost and 3R-compatible in vitro screening of otoprotective and otoregenerative drug candidates. This study may also add new perspectives to the field of inner ear regeneration.
全球有超过 4.6 亿人受到听力损失的影响,这是一个重大的社会经济负担。遗传和环境因素(例如,过度暴露于噪声、耳毒性药物治疗和衰老)都会促进耳蜗毛细胞和相关听觉神经元的不可逆退化,导致感音神经性听力损失。与鸟类、鱼类和两栖类动物不同,哺乳动物内耳由于听觉祖细胞的干性有限,几乎无法再生,也没有能够预防或逆转听力损失的因果治疗方法。截至目前,开发耳保护或耳再生治疗方法的主要限制是缺乏与高通量筛选候选药物兼容的有效临床前模型。目前,研究领域主要依赖于传统的内耳器官型培养物,导致变异性高、通量低、相关成本高和存在伦理问题。我们之前已经鉴定并表征了凤凰听觉神经前体细胞(ANPGs),它们是从 A/J 小鼠耳蜗中分离出来的高增殖祖细胞。在本研究中,我们旨在确定导致凤凰 ANPGs 固有高干性的信号通路。对传统低干性的 ANPGs(从 C57Bl/6 和 A/J 小鼠早期传代中分离得到)和高干性的凤凰 ANPGs 进行了转录组比较,鉴定了几个差异表达的通路。基于差异表达的通路,我们开发了一种重编程方案,以诱导衰老前 ANPGs(即来自 C57Bl6 小鼠)的高干性。WNT 激动剂(CHIR99021)和 TGFβ/Smad 抑制剂(LDN193189 和 SB431542)的联合使用导致衰老前神经球的生长显著增加,并且几乎可以无限扩展 ANPGs。与凤凰 ANPGs 一样,诱导干性的 ANPGs 可以冷冻和解冻,从而能够分发给其他实验室。重要的是,即使经过 20 代传代,诱导干性的 ANPGs 仍然能够分化为电生理成熟的 I 型听觉神经元。诱导干性的 ANPGs 和凤凰 ANPGs 解决了该领域的一个主要瓶颈,允许高效、高通量、低成本和 3R 兼容的体外筛选耳保护和耳再生候选药物。这项研究也可能为内耳再生领域增添新的视角。